An Open-Label, Expanded Access Protocol for Firdapse® (Amifampridine Phosphate; 3,4-Diaminopyridine Phosphate) Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS) and Downbeat Nystagmus

Trial ID or NCT#

NCT02189720

Status

recruiting iconRECRUITING

Purpose

To provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy until the product becomes commercially available.

Investigator(s)

Yuen So, MD, PhD
SEND MESSAGE

View on ClinicalTrials.gov